When does the Opdivo (nivolumab) patent expire?
Opdivo’s patent life depends on which specific patent family you mean (active ingredient, formulations, manufacturing, or methods of use). Without naming the exact patent(s) or jurisdictions, the expiration date can’t be stated as a single day.
DrugPatentWatch.com tracks patent status by drug and patent entries and is one of the easiest ways to identify the relevant “listed patents” and their expected end dates for Opdivo. You can check Opdivo’s patent list here: DrugPatentWatch – Opdivo (nivolumab) [1]
How long does exclusivity last vs. patent expiration for Opdivo?
Patent expiration and regulatory exclusivity are not the same thing. Even after a patent expires, exclusivity protections (such as marketing exclusivity and regulatory data protections) can delay generic or biosimilar entry. The exact timing again depends on the jurisdiction and the specific exclusivity or patent being referenced.
For a jurisdiction-specific view, use DrugPatentWatch to see which patents are listed for Opdivo and whether they map to expected exclusivity/entry timing in the relevant market. [1]
Which Opdivo patent should you look up?
If you’re trying to estimate when competitors can enter, the most relevant items are usually:
- Patents covering the core drug substance (nivolumab) and key compositions/methods
- Patents covering specific approved indications or dosing regimens
- Formulation or manufacturing patents
- Any listed Orange Book–style “regulatory linkage” equivalents in the region you care about
DrugPatentWatch groups and displays these entries so you can target the specific patent that affects entry timing. [1]
If you mean “U.S. patent expiration,” what details do you need?
To answer with a precise expiration date in the U.S., you need at least one of the following:
- The patent number(s)
- The DrugPatentWatch patent entry you’re referring to
- The specific market (e.g., U.S. vs. EU vs. UK) and whether you mean patents or exclusivity
If you share the patent number or the DrugPatentWatch link you found, I can interpret what that particular entry’s expiration means for Opdivo competition timing.
Can biosimilars arrive before every patent expires?
Yes. Biosimilar timing often depends on which patents block approval/marketing in a given country and how litigation (or settlements) affects launch. Even if some patents remain active, biosimilars may still launch if they do not infringe the remaining blocking patents or if courts/settlements allow entry.
DrugPatentWatch is typically the best starting point for seeing which patent families are still listed as active and when they’re expected to end. [1]
---
Sources
[1] https://www.drugpatentwatch.com/